Peter S. Conti, M.D., Ph.D., receives SNMMI 2016 Paul C. Aebersold Award

June 12, 2016

San Diego, Calif. -- Peter S. Conti, MD, PhD, FACNP, FACR, professor of radiology, pharmaceutical sciences and biomedical engineering, and director of the Molecular Imaging Center, Keck School of Medicine, University of Southern California, Los Angeles, has been named the 2016 recipient of the prestigious Paul C. Aebersold Award. Conti was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its annual meeting, held June 11-15 in San Diego, Calif.

The award is named for Paul C. Aebersold--a pioneer in the biologic and medical application of radioactive materials and the first director of the Atomic Energy Commission's Division of Isotope Development. It recognizes outstanding achievement in basic science applied to nuclear medicine and was first presented in 1973. The SNMMI Committee on Awards selects the recipient.

"Dr. Conti's innovative research has advanced the field of nuclear medicine and molecular imaging. He is a pioneer in the development of clinical applications of positron emission tomography," stated Gary L. Dillehay, MD, FACNM, FACR, chair of the SNMMI Committee on Awards and past president of the society. "His research includes the development of specific PET radiopharmaceuticals for imaging cancers and other disease processes, as well as the development of radiotracers for gene therapy."

Reflecting on the award, Conti said, "It is an incredible honor to receive this recognition from the Society and my peers. Passion, hard work and perseverance are critical factors in achieving success, but so too are having great mentors, collaborators, students, and of course, a supportive family. I have been very fortunate to have so many talented and caring people in my life, and for that I am truly grateful."

A tenured professor at the University of Southern California, Conti has served as director of the university's Molecular Imaging Center (formerly the Positron Imaging Science Center and Clinic) since its inception in 1991. His research focuses on development of novel diagnostic imaging agents for oncology applications. He pioneered the use of PET imaging in the understanding and characterization of cancer metabolism and gene expression, and he has focused on the discovery and clinical translation of novel PET imaging agents for in vivo cancer diagnosis, evaluation of metastatic disease potential and assessment of response to therapy.

Conti received his medical degree from Cornell University Medical College and his doctorate in biophysics from Cornell University Graduate School of Medical Sciences, Sloan-Kettering Division, New York, N.Y. He comped his residency in diagnostic radiology and fellowship in nuclear medicine at Johns Hopkins Medical Institutions, Baltimore, Md., and interned in the Department of Surgery at St. Luke's Hospital in New York, N.Y. Conti is board certified in both diagnostic radiology and nuclear medicine. He is a fellow of the American College of Radiology and the American College of Nuclear Medicine Physicians. He has published more than 300 peer-reviewed scientific articles and abstracts in the field of molecular imaging.

Conti is a past president of the Society of Nuclear Medicine and remains active in the society (now called the Society of Nuclear Medicine and Molecular Imaging), serving on a number of committees, including government and regulatory affairs related to the development of molecular imaging technology and its applications in medicine.
-end-
About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.

Society of Nuclear Medicine

Related Molecular Imaging Articles from Brightsurf:

New technique offers higher resolution molecular imaging and analysis
The new approach from Northwestern Engineering could help researchers understand more complicated biomolecular interactions and characterize cells and diseases at the single-molecule level.

Molecular imaging offers insight into therapy outcomes for neuroendocrine tumor patients
A new proof-of-concept study published in the May issue of The Journal of Nuclear Medicine has demonstrated that molecular imaging can be used for identifying early response to 177Lu-DOTATATE treatment in neuroendocrine tumor patients.

Non-invasive imaging method spots cancer at the molecular level
Researchers for the first time have combined a powerful microscopy technique with automated image analysis algorithms to distinguish between healthy and metastatic cancerous tissue without relying on invasive biopsies or the use of a contrast dye.

Molecular imaging suggests smokers may have impaired neuroimmune function
Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNM MI) shows preliminary evidence that tobacco smokers may have reduced neuroimmune function compared with nonsmokers.

Novel noninvasive molecular imaging for monitoring rheumatoid arthritis
A first-in-human Phase 1/Phase II study demonstrates that intravenous administration of the radiopharmaceutical imaging agent technetium-99m (99mTc) tilmanocept promises to be a safe, well-tolerated, noninvasive means of monitoring rheumatoid arthritis disease activity.

Improving molecular imaging using a deep learning approach
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed using a new deep learning approach to image reconstruction developed by researchers at Rensselaer Polytechnic Institute.

Nanoplatform developed with three molecular imaging modalities for tumor diagnosis
Nanotechnology and biotechnology are bringing us increasingly closer to personalised cancer treatment.

Study suggests molecular imaging strategy for determining molecular classifications of NSCLC
Recent findings suggest a novel positron emission tomography (PET) imaging approach determining epidermal growth factor receptor (EGFR) mutation status for improved lung cancer patient management.

New imaging technique able to watch molecular dynamics of neurodegenerative diseases
Researchers have developed a fast and practical molecular-scale imaging technique that could let scientists view never-before-seen dynamics of biological processes involved in neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.

Combined optical and molecular imaging could guide breast-conserving surgery
Breast-conserving surgery is the primary treatment for early-stage breast cancer, but more accurate techniques are needed to assess resection margins during surgery to avoid the need for follow-up surgeries.

Read More: Molecular Imaging News and Molecular Imaging Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.